Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer
Related Posts
Vadivelan A, Nemeth E, Ganz T, Bulut Y. Iron Deficiency Anemia in Children During and After PICU Stay: Single-Center Retrospective Cohort, 2021-2022. Pediatr Crit Care[...]
Li W, Rubin LH, Xu YH, Wang G, Li D, Vance DE. Plasma Protein Biomarkers for the Cognitive Functions in Women Living with HIV. Alzheimers[...]
McClellan SP, Rivera-Avila DA, Cardenas E, Pérez-Zepeda MU, Dykens JA, Weine SM, Fitzgibbon M, Ganz P, García-Peña C. RE: Enhancing Capacity for Primary Care Research[...]